BOEHRINGER-INGELHEIM
6.2.2020 08:32:09 CET | Business Wire | Press release
Boehringer Ingelheim announced today that its Respimat® re-usable inhaler device is the winner of the 2020 Pharmapack Eco-Design Award. The Pharmapack Awards celebrate the latest innovations from packaging companies within the drugs, medical devices, health products and veterinary drugs sectors.5
Respimat® re-usable is an enhanced version of the well-established Respimat® soft mist inhaler, providing benefits for the environment and patients.1,4 It significantly reduces waste and product carbon footprint (PCF)1,3,6 – while most disposable plastic inhaler devices need to be replaced after the medication provided is used up, Respimat® re-usable can be used with up to six medication cartridges before needing replacement.7,8,9 Respimat® is also propellant-free, meaning its CO2 emissions are 20 times lower than those of commonly used pressurized metered-dose inhalers.1,3 By 2025, it is expected that 776 tons of plastic waste and 14,300 tons of CO2 emissions will be prevented as a result of Respimat® re-usable. 776 tons of plastic waste equals more than 77.6 million 0.5-liter PET bottles.10 It was also designed to offer simplified handling, with an easy-to-read dose indicator, better grip for daily use and easy assembly, taking into account patient feedback.11
“We developed the Respimat® re-usable inhaler as part of our commitment to help patients and provide benefits beyond treatment,” said Dr. Paola Casarosa, Head of Global Therapeutic Areas at Boehringer Ingelheim. “Respimat® re-usable is the result of patient feedback, providing an inhaler with enhancements such as simplified handling and an easy-to-read dose indicator, and significantly reduced impact on the environment.11 A very important aim of Boehringer Ingelheim is to lower greenhouse gases and reduce waste, so we’re proud to be recognized for our efforts in this area.”
Boehringer Ingelheim views safeguarding the planet as an essential prerequisite wherever possible and maintains a focus on environmental protection.12 That is one of the major reasons Boehringer Ingelheim continues to invest in innovation and initiatives to protect the environment.12
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about Boehringer Ingelheim’s receipt of the Pharmapack 2020 Eco-Design Award.
For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/respimat-re-usable-wins-pharmapack-eco-design-award
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005611/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp and Elastio Announce Partnership to Deliver Defense-in-Depth Ransomware Resilience24.3.2026 13:00:00 CET | Press release
Robust cyber resilience requires both perimeter defenses and built-in security at the storage layer NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Elastio are helping enterprises enhance their cyber resilience with a layered defense that extends from production storage into recovery data. Security teams must be ready to address threats at every layer of their technology stack, including ransomware that moved quietly through production before it was caught that now lives inside snapshots and backups. Advanced ransomware is engineered to evade prevention tools, moving quietly through production, staying below detection thresholds, reaching backup data before any alert is triggered. "As we migrated our infrastructure, ensuring we had the right level of backup security and assurance was non-negotiable,” Marc Crudgington, VP IT Infrastructure and CISO, Crane WW Logistics. “Elastio provided continuous inspection of our backups from day one - giving us confidence in
NetApp and Commvault Advance Cyber Resilience with Strategic Alliance24.3.2026 13:00:00 CET | Press release
Joint unified cyber resilience solution delivers data security and rapid recovery across hybrid environments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Commvault (NASDAQ: CVLT), a leader in unified resilience at enterprise scale, today announced a strategic alliance to deliver a powerful, integrated solution for enterprise data protection and cyber resilience. The unified solution enables resilience, security, and rapid recovery for customers across on-premises and cloud environments, giving organizations confidence that their data is always available, immutable, and recoverable. “This alliance reinforces NetApp and Commvault’s leadership in the rapidly evolving cyber resilience and data protection market,” said Dallas Olson, Chief Commercial Officer at NetApp. “Together we’re helping customers make their infrastructure intelligent and secure so they have the confidence that their data is always available, protected, and recoverable—no matter where it live
SBC Medical Announces Next-Generation Wellness Strategy “SBC Wellness 2.0”24.3.2026 13:00:00 CET | Press release
Pioneering the “Performance Medicine” category for full-scale entry into the longevity market — targeting a global market projected to reach $2 trillion by 2035 SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced “SBC Wellness 2.0,” a new wellness and longevity platform that combines aesthetic healthcare, preventative care, and data-driven health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323000188/en/ SBC Medical Announces Next-Generation Wellness Strategy “SBC Wellness 2.0” The initiative positions SBC Medical to participate in the fast-growing longevity market, which is projected to reach approximately $800 billion in 2025* and expand to approximately $2 trillion by 2035, with a compound annual growth rate exceeding 10% from 2026 to 2035. Th
Andy Walsky of ExaGrid Honored as A 2026 CRN EMEA Channel Leader24.3.2026 13:00:00 CET | Press release
ExaGrid®, the leader in Tiered Backup Storage, today announced that CRN UK—a brand of The Channel Company—has selected Andy Walsky, VP of EMEA & APAC Sales, for inclusion on the prestigious 2026 CRN® Channel Leaders EMEA list. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324173870/en/ ExaGrid works with resellers and distributors worldwide. The ExaGrid channel programs are designed to be easy for partners, with support from the ExaGrid sales team and without milestone commitments. ExaGrid is known for having a Tiered Backup Storage system that “just works,” is not oversold or undersized, and provides its customers with the best customer support in the industry with an assigned level 2 technical support engineer, ensuring that partners’ customers are well ta
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights24.3.2026 12:30:00 CET | Press release
COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profileAcross three large trials in TRD, including two positive Phase 3 studies, COMP360’s differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved beforeCompass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launchPhase 2b/3 trial in PTSD initiating, following FDA acceptance of IND applicationSuccessful $150 million financing in February and exercise of $200 million in warrants extends cash runway into 2028 Compass Pathways plc (Nasdaq: CMPS), a biote
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom